Trial record 20 of 1638 for:
Open Studies | "Lymphatic Diseases"
EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Chang Gung Memorial Hospital.
Recruitment status was Recruiting
Information provided by (Responsible Party):
CHIH-HSI KUO, Chang Gung Memorial Hospital
First received: November 21, 2011
Last updated: December 15, 2011
Last verified: December 2011
This study aims on the combinatorial results of cytology, histopathology and microbiology obatined by EBUS-TBNA for unselected mediastina lesions.
||Observational Model: Case-Only
Time Perspective: Prospective
||EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy
Primary Outcome Measures:
- Diagnostic rate [ Time Frame: Participant will be followed within an average of three months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2012 (Final data collection date for primary outcome measure)
A number of studies have proved EBUS-TBNA to be useful for lymph node staging in lung cancer. The diagnostic performance is equivalent to mediastinoscopy while the invasiveness is far less. This study primarily focusing on merged approach of cytology, histopathology and microbioloogy obatined by EBUS-TBNA for unselected mediastina lesions.
|Ages Eligible for Study:
||18 Years to 90 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with mediastinal lymphadenopathy on Chest CT scan with a short-axis > 10mm
- Age > 18 years old
- mediastinal lymphadenopathy on Chest CT scan
- with a short-axis > 10mm
- patients intolerant to bronchoscopy exam
- unstable vital sign (Blood pressure, heart rate, breath rate)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01493739
|Chang Gung Memorial Hospital
|Taipei, Taiwan, 112 |
|Contact: Chih-Hsi Kuo, MD email@example.com |
|Principal Investigator: Chih-Hsi Kuo, MD |
Chang Gung Memorial Hospital
||Chih-Hso Kuo, MD
||Chang Gung Memorial Hospital
No publications provided
||CHIH-HSI KUO, Principle Investigator, Consultant Physician, Respiratory Medicine Department, Chang Gung Memorial Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 21, 2011
||December 15, 2011
||Taiwan: Department of Health
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 18, 2014
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases